Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

Data describing the long-term efficacy and tolerability of inclisiran are limited. This was explored in ORION-8, an open-label extension of preceding Phase 2 and Phase 3 placebo-controlled and open-label extension trials.